Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol vs GC+HCQ in pregnant RA patients
NCT04569890Unknown
- Sponsor
- Renji Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Randomised, single-blind trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by Renji Hospital. Primary endpoint: Disease Activity Score 28 at 24 weeks. Status: unknown.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04569890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569890.